<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01772290</url>
  </required_header>
  <id_info>
    <org_study_id>GP28465</org_study_id>
    <nct_id>NCT01772290</nct_id>
  </id_info>
  <brief_title>A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib</brief_title>
  <official_title>A Clinical Drug-Drug Interaction Study to Evaluate the Effect of a Proton Pump Inhibitor, a Combined P-gp/CYP3A4 Inhibitor, and a CYP2C9 Inhibitor on the Pharmacokinetics of Vismodegib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This randomized, open-label, 4-arm, multiple-dose study will evaluate the effect of
      coadministration of a protein pump inhibitor, an inhibitor of P-glycoprotein and CYP3A4, or
      an inhibitor of CYP2C9 on the pharmacokinetics of vismodegib in healthy female subjects of
      non-childbearing potential. Subjects will be randomized to receive multiple oral doses of
      vismodegib, alone or in combination with multiple oral doses of either rabeprazole,
      itraconazole or fluconazole. Anticipated time on study treatment is up to 11 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative effect of rabeprazole on steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css)</measure>
    <time_frame>up to 12 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative effect of itraconazole on steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css)</measure>
    <time_frame>up to 12 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative effect of fluconazole on the steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css)</measure>
    <time_frame>up to 12 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>A: Vismodegib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Rabeprazole + Vismodegib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Itraconazole + Vismodegib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D: Fluconazole + Vismodegib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluconazole</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>D: Fluconazole + Vismodegib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itraconazole</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>C: Itraconazole + Vismodegib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rabeprazole</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>B: Rabeprazole + Vismodegib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vismodegib</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>A: Vismodegib</arm_group_label>
    <arm_group_label>B: Rabeprazole + Vismodegib</arm_group_label>
    <arm_group_label>C: Itraconazole + Vismodegib</arm_group_label>
    <arm_group_label>D: Fluconazole + Vismodegib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females of non-childbearing potential

          -  Body mass index (BMI) 18 to 32 kg/m2, inclusive

          -  In good health, determined by no clinically significant findings from medical history,
             physical examination. 12-lead ECG, and vital signs

          -  Clinical laboratory evaluations, complete blood count and urinalysis within the normal
             range for the test laboratory, unless not deemed clinically significant by the
             investigator

          -  Negative test for drugs of abuse at screening and check-in (including alcohol)

          -  Negative for hepatitis B, hepatitis C and HIV infection

          -  Non-childbearing potential is defined as: non-pregnant, non-lactating, and either
             postmenopausal for at least 1 year or surgically sterile (e.g. bilateral oophorectomy
             and/or hysterectomy)

        Exclusion Criteria:

          -  Significant history or clinical evidence of any metabolic (including type 1 or 2
             diabetes). allergic, dermatological, hepatic, renal, hematological, pulmonary,
             cardiovascular, endocrine, GI (including gastric or duodenal ulcers),
             Zollinger-Ellison syndrome, Barrett's esophagus, urological, neurological, or
             psychiatric disorder

          -  History of inflammatory arthritis

          -  History of symptomatic hypotension

          -  History of seizure disorders

          -  History of bipolar or major depressive disorder

          -  History of stomach or intestinal surgery or resection that would potentially alter
             absorption and/or excretion of orally administered drugs (appendectomy, hernia repair,
             and/or cholecystectomy will be allowed)

          -  History of alcoholism or drug addiction within 1 year prior to check-in

          -  Use of any tobacco- or nicotine-containing products within 6 months prior to check-in

          -  Participation in any other investigational study drug or biological agent trial in
             which receipt of investigational study drug occurred within 5 half-lives or 30 days,
             whichever is longer, prior to check-in

          -  Use of PPIs, H2-receptor antagonists, or antacids within 1 month prior to check-in

          -  History of chronic PPI use (&gt; 30 days of continuous daily dosing) within 6 months of
             check-in
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2013</study_first_submitted>
  <study_first_submitted_qc>January 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2013</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

